title: Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
abstract: The World Health Organization released recommendations on treatment, prevention, and infant feeding practices within the context of HIV infection based on the "latest scientific evidence" available. The "Rapid Advice" document anticipates the release of official HIV Prevention-of-Mother-to-Child Transmission guidelines. As investigators involved in public health programs providing HIV care in sub-Saharan Africa, we are concerned about the ramifications of specific recommendations, often viewed as dogma by policy makers in this setting. The recommendation that CD4 cell counts be available antenatally so that decisions can be made regarding maternal antiretroviral eligibility is problematic because the ability to measure CD4 cells is nonexistent in many African health centers. As a result, antiretroviral treatment initiation in pregnancy will either be unnecessarily delayed or patients in need of treatment may receive prolonged courses of monotherapy. It is critical that exceptions be made for populations without access to flow cytometry. Another point of concern is that the massive unrestricted use of efavirenz during pregnancy is encouraged. Given that surveillance of pregnancy outcomes is not routinely performed in such settings and in light of the teratogenic potential of efavirenz (contraindicated during the first trimester in developed countries), we are concerned that its indiscriminate use will lead to further problems in vulnerable populations. Another premature recommendation is the use of daily administration of nevirapine to HIV-exposed infants throughout the entire duration of breastfeeding. Results of clinical trials documenting the efficacy of this approach for extended periods of time are not yet available. Single dose nevirapine has been shown to compromise future treatment options in HIV-infected women and infants. In addition, the long-term safety profile of this agent in immune-competent infants has not been established. In summary, although the guidelines do underscore major advances in the field, specific caveats are not yet supported by existing data.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Palombi
authors.forename: Karin
authors.initials: K
authors.lastname: Nielsen-Saines
authors.forename: Marina
authors.initials: M
authors.lastname: Giuliano
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Marazzi
mesh_terms: D017954:Africa South of the Sahara / Q000453:epidemiology; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D048588:Benzoxazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001942:Breast Feeding; D018791:CD4 Lymphocyte Count / Q000706:statistics & numerical data; D002648:Child; D003521:Cyclopropanes; D005260:Female; D005434:Flow Cytometry / Q000706:statistics & numerical data; D014943:Global Health; D006678:HIV / Q000187:drug effects / Q000254:growth & development*; D015658:HIV Infections / Q000188:drug therapy / Q000208:ethnology / Q000517:prevention & control / Q000635:transmission / Q000821:virology; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D057766:Policy; D017410:Practice Guidelines as Topic / Q000592:standards; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D011634:Public Health / Q000592:standards
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D019829:Nevirapine; C098320:efavirenz